Executive Change

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) ______________   Delaware (State or other jurisdiction of incorporation)       1-07151 (Commission File Number)       31-0595760 (I.R.S. Employer Identification No.)   1221 Broadway , Oakland , California   94612-1888 (Address of principal executive offices) (Zip code)   ( 510 ) 271-7000 (Registrant's telephone number, including area code)   Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ]       Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)       [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)       [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))       [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Title of each class Symbol(s) Name of each exchange on which registered Common Stock - $1.00 par value CLX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company           ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On March 2, 2022, The Clorox Company (the “Company”) announced that Tony Matta, Executive Vice President – Chief Growth Officer of the Company, would be leaving the Company, effective March 11, 2022. In addition, the Company announced that Stacey Grier, currently Senior Vice President – Chief Marketing and Strategy Officer, is being promoted to the role of Executive Vice President – Chief Growth & Strategy Officer, effective March 14, 2022. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CLOROX COMPANY       Date: March 2, 2022 By:     /s/ Angela Hilt Angela Hilt   Senior Vice President – Chief Legal Officer